These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 38784348)

  • 1. Stepwise Incremental Dose Schedule of Sirolimus Is Successfully Tolerated by a Patient With Lymphangioleiomyomatosis Who Was Initially Allergic to mTOR Inhibitors.
    Seyama K; Komiyama E; Tsuchihashi H; Okura MK; Sekimoto Y; Mitsuishi Y
    Cureus; 2024 Apr; 16(4):e58805. PubMed ID: 38784348
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Everolimus treatment of abdominal lymphangioleiomyoma in five women with sporadic lymphangioleiomyomatosis.
    Mohammadieh AM; Bowler SD; Silverstone EJ; Glanville AR; Yates DH
    Med J Aust; 2013 Jul; 199(2):121-3. PubMed ID: 23879512
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of sirolimus in the treatment of lymphangioleiomyomatosis: favorable responses in patients with different extrapulmonary manifestations.
    Freitas CS; Baldi BG; Araújo MS; Heiden GI; Kairalla RA; Carvalho CR
    J Bras Pneumol; 2015; 41(3):275-80. PubMed ID: 26176526
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical features, epidemiology, and therapy of lymphangioleiomyomatosis.
    Taveira-DaSilva AM; Moss J
    Clin Epidemiol; 2015; 7():249-57. PubMed ID: 25897262
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Successful treatment of a patient with chyluria due to lymphangioleiomyomatosis using sirolimus.
    Sakaue T; Tominaga M; Niizeki T; Zaizen Y; Matsukuma K; Koganemaru M; Hoshino T; Torimura T
    Respir Med Case Rep; 2018; 23():86-89. PubMed ID: 29349035
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of low-dose sirolimus for treatment of lymphangioleiomyomatosis.
    Ando K; Kurihara M; Kataoka H; Ueyama M; Togo S; Sato T; Doi T; Iwakami S; Takahashi K; Seyama K; Mikami M
    Respir Investig; 2013 Sep; 51(3):175-83. PubMed ID: 23978644
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Additional Octreotide Therapy to Sirolimus Achieved a Decrease in Sirolimus-refractory Chylous Effusion Complicated with Lymphangioleiomyomatosis.
    Namba M; Masuda T; Nakamura T; Horimasu Y; Miyamoto S; Nakashima T; Iwamoto H; Fujitaka K; Hamada H; Hattori N
    Intern Med; 2017 Dec; 56(24):3327-3331. PubMed ID: 29021448
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Successful Treatment of Postmenopausal Exacerbation of Abdominal Lymphangioleiomyomatosis With Sirolimus: A Report of a Rare Case.
    Uchida K; Tobino K
    Cureus; 2024 Sep; 16(9):e69549. PubMed ID: 39416572
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management of lymphangioleiomyomatosis.
    Taveira-DaSilva AM; Moss J
    F1000Prime Rep; 2014; 6():116. PubMed ID: 25580270
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lymphangioleiomyomatosis: a disease involving the lymphatic system.
    Seyama K; Kumasaka T; Kurihara M; Mitani K; Sato T
    Lymphat Res Biol; 2010 Mar; 8(1):21-31. PubMed ID: 20235884
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Changes in lung function and chylous effusions in patients with lymphangioleiomyomatosis treated with sirolimus.
    Taveira-DaSilva AM; Hathaway O; Stylianou M; Moss J
    Ann Intern Med; 2011 Jun; 154(12):797-805, W-292-3. PubMed ID: 21690594
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lymphangioleiomyomatosis: differential diagnosis and optimal management.
    Xu KF; Lo BH
    Ther Clin Risk Manag; 2014; 10():691-700. PubMed ID: 25187723
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sirolimus decreases circulating lymphangioleiomyomatosis cells in patients with lymphangioleiomyomatosis.
    Cai X; Pacheco-Rodriguez G; Haughey M; Samsel L; Xu S; Wu HP; McCoy JP; Stylianou M; Darling TN; Moss J
    Chest; 2014 Jan; 145(1):108-112. PubMed ID: 24051985
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Functional improvements in patients with lymphangioleiomyomatosis after sirolimus: an observational study.
    Zhan Y; Shen L; Xu W; Wu X; Zhang W; Wang J; Li X; Yang Y; Tian X; Xu KF
    Orphanet J Rare Dis; 2018 Feb; 13(1):34. PubMed ID: 29458386
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of mTOR inhibitors on the mortality and safety of patients with lymphangioleiomyomatosis on the lung transplantation waitlist: A retrospective cohort study.
    Sakurai T; Kanou T; Funaki S; Fukui E; Kimura T; Ose N; Inoue Y; Shintani Y
    Respir Investig; 2024 Jul; 62(4):657-662. PubMed ID: 38761480
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of beta-agonists on LAM progression and treatment.
    Le K; Steagall WK; Stylianou M; Pacheco-Rodriguez G; Darling TN; Vaughan M; Moss J
    Proc Natl Acad Sci U S A; 2018 Jan; 115(5):E944-E953. PubMed ID: 29339522
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of cells cultured from chylous effusion from a patient with sporadic lymphangioleiomyomatosis.
    Grzegorek I; Zuba-Surma E; Chabowski M; Janczak D; Szuba A; Dziegiel P
    Anticancer Res; 2015 Jun; 35(6):3341-51. PubMed ID: 26026094
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sirolimus Suppresses Phosphorylation of Cofilin and Reduces Interstitial Septal Thickness in Sporadic Lymphangioleiomyomatosis.
    Huang YL; Chen PR; Lai YJ; Hsu HH
    Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445268
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Case report: If it is not asthma-think of lymphangioleiomyomatosis in younger female patients.
    Kirkeby MH; Bendstrup E; Rose HK
    Front Med (Lausanne); 2024; 11():1328471. PubMed ID: 38410750
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CA-125 in Disease Progression and Treatment of Lymphangioleiomyomatosis.
    Glasgow CG; Pacheco-Rodriguez G; Steagall WK; Haughey ME; Julien-Williams PA; Stylianou MP; Gochuico BR; Moss J
    Chest; 2018 Feb; 153(2):339-348. PubMed ID: 28576630
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.